Recent Updates
Recently added Catalysts
ATHE

Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen

Monday, September 21, 2020 4 min read
Key Takeaway: Director's Interest Notice Change of Director's Interest Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Introduced 30/9/2001. Name of Entity: Alterity

Full Press Release Details

Director's Interest Notice
Change of Director's Interest
Information or documents not available now must
be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.
Name of Entity: Alterity Therapeutics Limited (ASX:ATH)
ACN: 080 699 065
We (the entity) give ASX the following information
under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director: Mr. Brian Meltzer
Date of Last Notice: 22 nd December 2017
Part 1 - Change of director's relevant
interests in securities
In the case of a trust, this includes interests
in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which
come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. -
Date of change 18 th September 2020
No. of securities held prior to change Shares Options
Direct - 1,250,000
Indirect 326,666 -
Total 326,666 1,250,000
Class Unlisted Options
Number acquired Shares Options
Direct - 7,000,000
Indirect - -
Total - 7,000,000
+ See chapter 19 for defined terms.
11/3/2002 Appendix 3Y Page 1
Change of Director's Interest Notice
Number disposed Shares Options
Direct - -
Indirect - -
Total - -
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3 rd of September 2020.
No. of securities held after change Shares Options
Direct - 8,250,000
Indirect 326,666 -
Total 326,666 8,250,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Issue of incentive options under ESOP
Part 2 - Change of director's interests in contracts
Note: In the case of a company,
interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided on what date was this provided? N/A
The CFO Solution
22 Dec 2012
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 11/3/2002
Director's Interest Notice
Change of Director's Interest
Information or documents not available now must
be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.
Name of Entity: Alterity Therapeutics Limited (ASX:ATH)
ACN: 080 699 065
We (the entity) give ASX the following information
under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director: Dr. David Sinclair
Date of Last Notice: 8 th April 2019
Part 1 - Change of director's relevant
interests in securities
In the case of a trust, this includes interests
in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which
come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. -
Date of change 18 th September 2020
No. of securities held prior to change Shares Options
Direct - -
Indirect - -
Total - -
Class Unlisted Options
Number acquired Shares Options
Direct - 7,000,000
Indirect - -
Total - 7,000,000
+ See chapter 19 for defined terms.
11/3/2002 Appendix 3Y Page 1
Change of Director's Interest Notice
Number disposed Shares Options
Direct - -
Indirect - -
Total - -
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3 rd of September 2020.
No. of securities held after change Shares Options
Direct - 7,000,000
Indirect - -
Total - 7,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Issue of incentive options under ESOP
Part 2 - Change of director's interests in contracts
Note: In the case of a company,
interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided on what date was this provided? N/A
The CFO Solution
22 Dec 2012
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 11/3/2002
Director's Interest Notice
Change of Director's Interest
Information or documents not available now must
be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.
Name of Entity: Alterity Therapeutics Limited (ASX:ATH)
ACN: 080 699 065
We (the entity) give ASX the following information
under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director: Mr. Geoffrey Kempler
Date of Last Notice: 22 nd December 2017
Part 1 - Change of director's relevant
interests in securities
In the case of a trust, this includes interests
in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which
come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Director related entity
Date of change 18 th September 2020
No. of securities held prior to change Shares Options
Direct 30,000 5,000,000
Indirect 17,981,000 -
Total 18,011,000 5,000,000
Class Unlisted Options
Number acquired Shares Options
Direct - 14,000,000
Indirect - -
Total - 14,000,000
+ See chapter 19 for defined terms.
11/3/2002 Appendix 3Y Page 1
Change of Director's Interest Notice
Number disposed Shares Options
Direct - -
Indirect - -
Total - -
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3 rd of September 2020.
No. of securities held after change Shares Options
Direct 30,000 19,000,000
Indirect 17,981,000 -
Total 18,011,000 19,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Issue of incentive options under ESOP
Part 2 - Change of director's interests in contracts
Note: In the case of a company,
interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided on what date was this provided? N/A
The CFO Solution
22 Dec 2012
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 11/3/2002
Change of Director's Interest Notice
Change of Director's Interest
Information or documents not available now must
be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.
Name of Entity: Alterity Therapeutics Limited (ASX:ATH)
ACN: 080 699 065
We (the entity) give ASX the following information
under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director: Mr. Lawrence Gozlan
Date of Last Notice: 22 nd December 2017
Part 1 - Change of director's relevant
interests in securities
In the case of a trust, this includes interests
in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which
come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. -
Date of change 18 th September 2020
No. of securities held prior to change Shares Options
Direct - 1,250,000
Indirect - -
Total - 1,250,000
Class Unlisted Options
Number acquired Shares Options
Direct - 7,000,000
Indirect - -
Total - 7,000,000
+ See chapter 19 for defined terms.
11/3/2002 Appendix 3Y Page 1
Change of Director's Interest Notice
Number disposed Shares Options
Direct - -
Indirect - -
Total - -
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3 rd of September 2020.
No. of securities held after change Shares Options
Direct - 8,250,000
Indirect - -
Total - 8,250,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Issue of incentive options under ESOP
Tags: ATHE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Sep 21, 2020